Clinical trial
R115777 in Treating Patients With Advanced Bladder Cancer
NCT00006376 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00006376 |
|---|---|
| Title | R115777 in Treating Patients With Advanced Bladder Cancer |
| Official title | A Phase II Trial of R115777, an Oral Farnesyltransferase Inhibitor (FTI) in Previously Untreated Patients With Advanced Urothelial Tract Transitional Cell Carcinoma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter |
| Intervention type | Drug |
| Interventions | chemotherapy, tipifarnib |
| Start date | Mar 1, 2000 |
| Completion | May 1, 2005 |
| First posted | Apr 2, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: